Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 66

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury

Fontana, Robert J., Bjornsson, Einar S., Reddy, Rajender, Andrade, Raul J. · 2023 · Clinical Gastroenterology and Hepatology

Abstract

Idiosyncratic drug induced liver injury (DILI) is an infrequent but important cause of liver disease. Newly identified causes of DILI include the COVID vaccines, turmeric, green tea extract, and immune checkpoint inhibitors. DILI is largely a clinical diagnosis of exclusion that requires evaluation for more common causes of liver injury and a compatible temporal association with the suspect drug. Recent progress in DILI causality assessment includes the development of the semi-automated Revised Electronic Causality Assessment Method (RECAM) instrument. In addition, a number of drug specific HLA associations have been identified which can help with the confirmation or exclusion of DILI in individual patients. Various prognostic models can help identify the 5 to 10% of patients at highest risk of death. Following suspect drug cessation, 80% of DILI patients will fully recover while 10 to 15% have persistently abnormal labs at 6 months of follow-up. Hospitalized DILI patients with an elevated INR or mental status changes should be considered for N-acetylcysteine therapy and urgent liver transplant evaluation. Selected patients with moderate to severe DRESS or autoimmune features on liver biopsy may benefit from short-term corticosteroids. However, prospective studies are needed to determine the optimal patients and dose and duration of steroids to use. LiverTox is a comprehensive, freely accessible website with important information regarding the hepatotoxicity profile of over 1000 approved medications and 60 HDS products. Ongoing "omics" studies will hopefully lead to additional insight into DILI pathogenesis, improved diagnostic and prognostic biomarkers and mechanism-based treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2022.12.040

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 62

  1. Sgro, 2002, Incidence of drug-induced hepatic injuries: a French population-based study, Hepatology, 36, 451, 10.1053/jhep.2002.34857 · DOI · Paper page
  2. DiPaola, 2019, Antimicrobials and antiepileptics are the leading causes of idiosyncratic drug-induced liver injury in American children, J Pediatr Gastroenterol Nutr, 69, 152, 10.1097/MPG.0000000000002383 · DOI · Paper page
  3. George, 2018, Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury, Regul Toxicol Pharmacol, 94, 101, 10.1016/j.yrtph.2018.01.018 · DOI · Paper page
  4. Hoofnagle, 2021, HLA-B ∗ 35:01 and green-tea induced liver injury, Hepatology, 73, 2484, 10.1002/hep.31538 · DOI · Paper page
  5. Vuppalanchi R, Bonkovsky HL, Ahmad J, et al. Garcinia cambogia either alone or in combination with green tea, causes moderate to severe liver injury. Clin Gastroenterol Hepatol. Published online June 20, 2022. https://doi.org/10.1016/j.cgh.2021.08.015. · DOI
  6. Halegoua-DeMarzio, 2022, Liver injury associated with turmeric, a growing problem: ten cases from the Drug-Induced Liver Injury Network, Am J Med December
  7. Stolz, 2019, Severe and protracted cholestasis in 44 young mean taking bodybuilding supplements: assessment of genetic, clinical, and chemical risk factors, Aliment Pharmacol Ther, 49, 1195, 10.1111/apt.15211 · DOI
  8. Chalasani, 2022, Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study, J Hepatol, 76, 832, 10.1016/j.jhep.2021.12.013 · DOI
  9. Björnsson, 2022, Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment, J Hepatol, 76, 86, 10.1016/j.jhep.2021.08.024 · DOI · Paper page
  10. Miller, 2020, Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors, Am J Gastroenterol, 115, 261, 10.14309/ajg.0000000000000398 · DOI
  11. Yoshikawa, 2021, A case with life-threatening secondary sclerosing cholangitis caused by nivolumab, Clin J Gastroenterol, 14, 283, 10.1007/s12328-020-01287-1 · DOI
  12. Björnsson, 2022, Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports, Hepatol Commun, 6, 1895, 10.1002/hep4.1959 · DOI · Paper page
  13. Kukkarni, 2022, Tinospora cofdifolia (Giloy)–induced liver injury during the COVID-19 pandemic: multicenter nationwide study from India, Hepatol Commun, 6, 1289, 10.1002/hep4.1904 · DOI
  14. Chow, 2022, Autoimmune hepatitis-like syndrome following COVID-19 vaccination: a systematic review of the literature, Dig Dis Sci, 67, 4574, 10.1007/s10620-022-07504-w · DOI
  15. Efe, 2022, Liver injury after SARS-CoV-2 vaccination: features of immune mediated hepatitis, role of corticosteroid therapy, and outcome, Hepatology, 76, 1576, 10.1002/hep.32572 · DOI · Paper page
  16. Ahmad, 2021, Liver injury associated with a popular opioid-like product: experience from the US DILIN and a review of the literature, Drug Alcohol Depend, 218, 10.1016/j.drugalcdep.2020.108426 · DOI · Paper page
  17. Fontana, 2009, DILIN prospective study: rationale, design, and conduct, Drug Saf, 32, 55, 10.2165/00002018-200932010-00005 · DOI · Paper page
  18. Fontana, 2022, Incidence of hepatitis E infection in American patients with suspected drug-induced liver injury is low and declining: the DILIN Prospective study, Am J Gastroenterol, 117, 1462, 10.14309/ajg.0000000000001869 · DOI
  19. Ahmad, 2019, Importance of hepatitis C virus RNA testing in patients with suspected drug-induced liver injury, Dig Dis Sci, 64, 2645, 10.1007/s10620-019-05591-w · DOI
  20. Alpers, 2023, Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease: an analysis of pivotal clinical trials, Am J Kidney Dis, 81, 281, 10.1053/j.ajkd.2022.08.012 · DOI
  21. Kleiner, 2014, Hepatic histological findings in suspected drug-induced liver injury. Systematic evaluation and clinical associations, Hepatology, 59, 661, 10.1002/hep.26709 · DOI · Paper page
  22. Ahmad, 2022, Value of liver biopsy in the diagnosis of DILI, J Hepatol, 76, 1070, 10.1016/j.jhep.2021.12.043 · DOI · Paper page
  23. Bjornsson, 2016, Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports, Hepatology, 63, 59, 10.1002/hep.28323 · DOI · Paper page
  24. Bjornsson, 2015, Discrepancies in liver disease labelling in the package inserts of commonly prescribed medications, Gastroenterology, 149, 269, 10.1053/j.gastro.2014.12.007 · DOI · Paper page
  25. Wu, 2021, A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labelling reveals discrepancies, Drug Discov Today, 27, 337, 10.1016/j.drudis.2021.09.009 · DOI · Paper page
  26. Danan, 2016, RUCAM in drug and herb induced liver injury: the update, Int J Mol Sci, 27, 14
  27. Devarbhavi, 2022, Comparison of Roussel-Uclaf causality assessment method (RUCAM) versus revised electronic causality assessment method (RECAM): analysis of 100 cases from an Indian Registry, Hepatology, 76
  28. Li, 2019, HLA-B ∗ 35:01 allele is a potential biomarker for predicting polygonum multiforum induced liver injury in humans, Hepatology, 70, 346, 10.1002/hep.30660 · DOI · Paper page
  29. Cirulli, 2019, A missense variant in PTPN22 is a risk factor for drug-induced liver injury, Gastroenterology, 156, 1707, 10.1053/j.gastro.2019.01.034 · DOI · Paper page
  30. Church, 2019, Candidate biomarkers for the diagnosis and prognosis of DILI: an international collaborative effort, Hepatology, 69, 767, 10.1002/hep.29802 · DOI · Paper page
  31. Wagner, 2021, Safety and disease monitoring biomarkers in Duchenne muscular dystrophy: results from a phase II trial, Biomark Med, 15, 1389, 10.2217/bmm-2021-0222 · DOI
  32. Llewellyn, 2021, Evaluating the sensitivity and specificity of promising circulating biomarkers to diagnose liver injury in humans, Toxicol Sci, 181, 23, 10.1093/toxsci/kfab003 · DOI
  33. Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006 · DOI · Paper page
  34. Andrade, 2005, Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period, Gastroenterology, 129, 512, 10.1016/j.gastro.2005.05.006 · DOI · Paper page
  35. Hayashi, 2017, Death and liver transplantation within 2 years of onset of drug-induced liver injury, Hepatology, 66, 1275, 10.1002/hep.29283 · DOI · Paper page
  36. Fontana, 2014, DILIN Network. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset, Gastroenterology, 147, 96, 10.1053/j.gastro.2014.03.045 · DOI · Paper page
  37. Chalasani, 2017, Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to Caucasians, Am J Gastroenterol, 112, 1382, 10.1038/ajg.2017.215 · DOI · Paper page
  38. Stephens, 2021, Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry, J Hepatol, 75, 86, 10.1016/j.jhep.2021.01.029 · DOI · Paper page
  39. Ghabril, 2019, Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected DILI, Gastroenterology, 157, 1245, 10.1053/j.gastro.2019.07.006 · DOI · Paper page
  40. Robles-Diaz, 2014, Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with DILI, Gastroenterology, 147, 109, 10.1053/j.gastro.2014.03.050 · DOI · Paper page
  41. Lewis, 2021, Effects of bardoxolone methyl on hepatic enzymes in patients with type 2 diabetes mellitus and stage 4 CKD, Clin Transl Sci, 14, 299, 10.1111/cts.12868 · DOI
  42. Fontana, 2015, Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug-induced liver injury, Am J Gastroenterol, 110, 1450, 10.1038/ajg.2015.283 · DOI · Paper page
  43. Medina-Caliz, 2016, Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury, J Hepatol, 65, 532, 10.1016/j.jhep.2016.05.003 · DOI · Paper page
  44. Björnsson, 2022, Long-term sequelae of drug-induced liver injury, J Hepatol, 76, 435, 10.1016/j.jhep.2021.10.011 · DOI
  45. Björnsson, 2022, Role of corticosteroids in drug-induced liver injury: a systematic review, Front Pharmacol, 13, 10.3389/fphar.2022.820724 · DOI · Paper page
  46. Karkhanis, 2014, Steroid use in ALF, Hepatology, 59, 612, 10.1002/hep.26678 · DOI · Paper page
  47. Tsung, 2019, Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy, Aliment Pharmacol Ther, 50, 800, 10.1111/apt.15413 · DOI · Paper page
  48. Swanson LA, Kassab I, Tsung I, et al. Liver injuring during durvulumab-based immunotherapy is associated with poorer patient survival: a retrospective analysis. Front Oncol. Published online October 24, 2022. https://doi.org/10.3389/fonc.2022.984940 · DOI · Paper page
  49. Bessone, 2022, Checkpoint inhibitor-induced hepatoxicity: role of liver biopsy and management approach, World J Hepatol, 14, 1269, 10.4254/wjh.v14.i7.1269 · DOI
  50. Schneider, 2021, Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update, J Clin Oncol, 39, 4073, 10.1200/JCO.21.01440 · DOI · Paper page
  51. Fecher, 2022, The role of tissue biopsy in the management of immune checkpoint inhibitor toxicity, J Natl Compr Canc Netw, 20, 417, 10.6004/jnccn.2022.7011 · DOI
  52. Lee, 2009, Acute Liver Failure Study Group. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure, Gastroenterology, 137, 856, 10.1053/j.gastro.2009.06.006 · DOI · Paper page
  53. Moosa, 2021, A randomized controlled trial of intravenous N-acetylcysteine in the management of anti-tuberculosis drug-induced liver injury, Clin Infect Dis, 73, e3377, 10.1093/cid/ciaa1255 · DOI · Paper page
  54. Squires, 2013, Pediatric Acute Liver Failure Study Group. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial, Hepatology, 57, 1542, 10.1002/hep.26001 · DOI · Paper page
  55. Robles-Diaz, 2021, Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury. A systematic review, Front Pharmacol, 12, 10.3389/fphar.2021.744488 · DOI · Paper page
  56. Perrott, 2010, L-carnitine for acute valproic acid overdose: a systematic review of published cases, Ann Pharmacother, 44, 1287, 10.1345/aph.1P135 · DOI · Paper page
  57. Devarbhavi, 2022, Leflunomide induced liver injury: differences in characteristics and outcomes in Indian and US registries, Liver Int, 42, 1323, 10.1111/liv.15189 · DOI
  58. Richardson, 2016, Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure, Blood, 127, 1656, 10.1182/blood-2015-10-676924 · DOI · Paper page
  59. Benic, 2022, Novel therapies for the treatment of drug-induced liver injury: a systematic review, Front Pharmacol, 12, 10.3389/fphar.2021.785790 · DOI
  60. Stine, 2016, Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review, Expert Rev Gastroenterol Hepatol, 10, 517, 10.1586/17474124.2016.1127756 · DOI · Paper page
  61. Niu, 2021, Prevention and management of idiosyncratic drug-induced liver injury: systematic review and meta-analysis of randomized clinical trials, Pharmacol Res, 164, 10.1016/j.phrs.2020.105404 · DOI · Paper page
  62. Rao, 2022, Secular trends in severe idiosyncratic drug-induced liver injury in North America: an update from the ALFSG Registry, Am J Gastroenterol, 117, 617, 10.14309/ajg.0000000000001655 · DOI · Paper page

Cited by

See all 66

Metadata

Authors
Fontana, R. J., Bjornsson, E. S., Reddy, R., & Andrade, R. J.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2023-07
Volume
21
Issue
8
Pages
2088-2099
ISSN
1542-3565
Cited by
66
References
10
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Novo Nordisk
  • Spark Therapeutics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury. https://app.cochat.ai/papers/10.1016/j.cgh.2022.12.040
The paper
Fontana, R. J., Bjornsson, E. S., Reddy, R., & Andrade, R. J. (2023). The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2022.12.040

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.